<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01244633</url>
  </required_header>
  <id_info>
    <org_study_id>PSY301</org_study_id>
    <nct_id>NCT01244633</nct_id>
  </id_info>
  <brief_title>Ecopipam Treatment of Tourette Syndrome</brief_title>
  <official_title>Ecopipam Treatment of Tourette Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Psyadon Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Psyadon Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tourette's Syndrome is a neurological disease characterized by verbal and motor tics. The&#xD;
      currently available drug treatments are considered to be inadequate. This clinical trial is&#xD;
      designed to test if ecopipam is effective for the treatment of Tourette's Syndrome in adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tourette's Syndrome is a neurological disease characterized by verbal and motor tics.&#xD;
      Although its causes are unknown, many researchers believe that changes in brain chemicals&#xD;
      (called neurotransmitters) are critically involved. One of these neurotransmitters is called&#xD;
      dopamine, and it exerts its actions through its receptors (called D1-type or D2-type). It has&#xD;
      been suggested that the symptoms of Tourette's Syndrome are due to an overactivity at the&#xD;
      D1-type receptor. Ecopipam is a selective antagonist of the D1-type receptors. The present&#xD;
      clinical trial is designed to test if ecopipam is able to relieve the symptoms of the disease&#xD;
      in adults patients with Tourette's Syndrome. Eligible patients will be treated for eight&#xD;
      weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Yale Global Tic Severity Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Yale Global Tic Severity Score is a composite of subject reported severity of motor (range 0-25) and vocal (range 0-25) tics , as well as an impairment score (range 0-50). The outcome we are using is the Total Tic Severity score which is the sum of the motor and vocal tic severity scores (range 0-50). The higher the score on this scale, the more severe the symptoms. A positive drug effect is associated with a decrease from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adult Attention Deficit/Hyperactivity Disorder (ADHD) Self-report Symptom Checklist (ASRS)</measure>
    <time_frame>Every 7 days</time_frame>
    <description>This is a standard measure of ADHD severity that is typically used in these types of clinical trials.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Scale</measure>
    <time_frame>Every 7 days</time_frame>
    <description>This is a measure of feelings of depression that the patient might have.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Premonitory Urge for Tics Scale (PUTS-1)</measure>
    <time_frame>Every 7 days</time_frame>
    <description>This is a measure of the tic behavior that is seen in Tourette's patients, and it is typically used in these types of trials.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician Global Impression - Improvement and Severity Scales (CGI)</measure>
    <time_frame>End of trial</time_frame>
    <description>This is a measure of how the treating physician perceives the effectiveness of a drug treatment, and it is typically used in these types of clinical trials.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Assessments</measure>
    <time_frame>Every 7 days</time_frame>
    <description>Patients will be evaluated for any adverse events, and they will have a variety of blood tests to examine if any changes occur.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia Scale for Suicide Risk</measure>
    <time_frame>Every 7 days</time_frame>
    <description>This test monitors whether the patient has any feelings of committing self-harm. It is mandated by the FDA to include this scale in all clinical trials of new central nervous system drugs.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Tourette's Syndrome</condition>
  <arm_group>
    <arm_group_label>Ecopipam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ecopipam</intervention_name>
    <description>50 or 100 mg tablets given once per day for eight weeks</description>
    <arm_group_label>Ecopipam</arm_group_label>
    <other_name>SCH 39166</other_name>
    <other_name>PSYRX 101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have TS (Tourette's Syndrome) based on the clinician-administered DCI&#xD;
             (Diagnostic Confidence Index) for TS.&#xD;
&#xD;
          -  Subjects must exhibit both motor and vocal tics.&#xD;
&#xD;
          -  Subjects must have exhibited tics for &gt;5 years.&#xD;
&#xD;
          -  Subjects must have a minimum score of 20 at both Screening and Baseline (just prior to&#xD;
             the first treatment) on the YGTSS (Yale Global Tic Severity Score).&#xD;
&#xD;
          -  Subjects must be age ≥ 18 years.&#xD;
&#xD;
          -  Women must be postmenopausal (&gt; 12 months without menses) or surgically sterile (i.e.,&#xD;
             by hysterectomy and/or bilateral oophorectomy) or must be using effective&#xD;
             contraception (i.e., oral contraceptives, intrauterine device, double barrier method&#xD;
             of condom and spermicide) and agree to continue use of contraception for the duration&#xD;
             of their participation in the study. Women of childbearing potential must agree to use&#xD;
             contraception for 30 days after their last dose of study drug.&#xD;
&#xD;
          -  Sexually active male subjects must use a barrier method of contraception during the&#xD;
             study and agree to continue the use of male contraception for at least 30 days after&#xD;
             the last dose of study drug.&#xD;
&#xD;
          -  Subject must execute a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have unstable medical illness or clinically significant abnormalities on&#xD;
             laboratory tests, or ECG at Screening.&#xD;
&#xD;
          -  Subjects with a major depressive episode in the past 2 years&#xD;
&#xD;
          -  Subjects with a history of attempted suicide&#xD;
&#xD;
          -  Subjects with clinically significant suicidality (score of ≥ 2 on Item 3 for the&#xD;
             Hamilton Depression Rating Scale [HAM-D])&#xD;
&#xD;
          -  Subjects with a first-degree relative with a major depressive episode that resulted in&#xD;
             any psychiatric hospitalization, attempted or completed suicide&#xD;
&#xD;
          -  Subjects with a history of seizures.&#xD;
&#xD;
          -  Subjects with a myocardial infarction within 6 months.&#xD;
&#xD;
          -  Women of childbearing potential who are currently pregnant or lactating.&#xD;
&#xD;
          -  Subjects who have a need for medication (other than ecopipam) with possible effects on&#xD;
             TS symptoms (i.e., lithium, naltrexone, methylphenidate, or psychostimulants),&#xD;
             unfavorable interactions with ecopipam (ie, dopamine agonists [including bupropion]),&#xD;
             or monoamine oxidase inhibitors.&#xD;
&#xD;
          -  Subjects with a lifetime history of bipolar disorder type I or II, dementia,&#xD;
             schizophrenia, or any psychotic disorder determined by the Structured Clinical&#xD;
             Interview for Diagnostic Statistical Manual IV Text Revision (DSM-IV-TR) Axis-I&#xD;
             Disorders (SCID).&#xD;
&#xD;
          -  Subjects with current or recent (past 3 months) DSM-IV substance abuse or dependence&#xD;
             (with the exception of nicotine).&#xD;
&#xD;
          -  Subjects with positive urine drug screen (cocaine, amphetamine, methamphetamine,&#xD;
             tetrahydrocannabinol (THC), benzodiazepines, barbiturates, phencyclidine (PCP),&#xD;
             opiates) at Screening. Subjects with urine positive only for benzodiazepines and/or&#xD;
             marijuana (i.e., a user but not an abuser as based on DSM-IV criteria) may be&#xD;
             eligible.&#xD;
&#xD;
          -  Subjects who have had previous treatment with ecopipam.&#xD;
&#xD;
          -  Subjects who have had treatment with:&#xD;
&#xD;
               -  investigational medication or depot neuroleptics within 3 months&#xD;
&#xD;
               -  fluoxetine within 6 weeks&#xD;
&#xD;
               -  other psychotropics with possible effects on TS symptoms (ie, lithium, or&#xD;
                  naltrexone) within 2 weeks prior to Screening.&#xD;
&#xD;
               -  oral neuroleptics within 2 weeks&#xD;
&#xD;
               -  selective serotonin reuptake inhibitors unless the dosage has been stable for a&#xD;
                  minimum of 4 weeks prior to study start&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Gilbert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Neuroscience Institute Overlook Hospital</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.psyadonrx.com</url>
    <description>Link to Sponsor's Website</description>
  </link>
  <reference>
    <citation>Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. J Pharmacol Exp Ther. 1988 Dec;247(3):1093-102.</citation>
    <PMID>2905002</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2010</study_first_posted>
  <results_first_submitted>March 12, 2015</results_first_submitted>
  <results_first_submitted_qc>August 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 29, 2015</results_first_posted>
  <last_update_submitted>August 27, 2015</last_update_submitted>
  <last_update_submitted_qc>August 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tourette's</keyword>
  <keyword>Ecopipam</keyword>
  <keyword>Dopamine receptors</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tourette Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ecopipam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ecopipam</title>
          <description>Active treatment&#xD;
Ecopipam: 50 or 100 mg tablets given once per day for eight weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ecopipam</title>
          <description>Active treatment&#xD;
Ecopipam: 50 or 100 mg tablets given once per day for eight weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Yale Global Tic Severity Score</title>
        <description>The Yale Global Tic Severity Score is a composite of subject reported severity of motor (range 0-25) and vocal (range 0-25) tics , as well as an impairment score (range 0-50). The outcome we are using is the Total Tic Severity score which is the sum of the motor and vocal tic severity scores (range 0-50). The higher the score on this scale, the more severe the symptoms. A positive drug effect is associated with a decrease from baseline.</description>
        <time_frame>8 weeks</time_frame>
        <population>Subjects completing the study</population>
        <group_list>
          <group group_id="O1">
            <title>Ecopipam</title>
            <description>Active treatment&#xD;
Ecopipam: 50 or 100 mg tablets given once per day for eight weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Yale Global Tic Severity Score</title>
          <description>The Yale Global Tic Severity Score is a composite of subject reported severity of motor (range 0-25) and vocal (range 0-25) tics , as well as an impairment score (range 0-50). The outcome we are using is the Total Tic Severity score which is the sum of the motor and vocal tic severity scores (range 0-50). The higher the score on this scale, the more severe the symptoms. A positive drug effect is associated with a decrease from baseline.</description>
          <population>Subjects completing the study</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adult Attention Deficit/Hyperactivity Disorder (ADHD) Self-report Symptom Checklist (ASRS)</title>
        <description>This is a standard measure of ADHD severity that is typically used in these types of clinical trials.</description>
        <time_frame>Every 7 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Depression Scale</title>
        <description>This is a measure of feelings of depression that the patient might have.</description>
        <time_frame>Every 7 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Premonitory Urge for Tics Scale (PUTS-1)</title>
        <description>This is a measure of the tic behavior that is seen in Tourette's patients, and it is typically used in these types of trials.</description>
        <time_frame>Every 7 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinician Global Impression - Improvement and Severity Scales (CGI)</title>
        <description>This is a measure of how the treating physician perceives the effectiveness of a drug treatment, and it is typically used in these types of clinical trials.</description>
        <time_frame>End of trial</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Assessments</title>
        <description>Patients will be evaluated for any adverse events, and they will have a variety of blood tests to examine if any changes occur.</description>
        <time_frame>Every 7 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Columbia Scale for Suicide Risk</title>
        <description>This test monitors whether the patient has any feelings of committing self-harm. It is mandated by the FDA to include this scale in all clinical trials of new central nervous system drugs.</description>
        <time_frame>Every 7 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ecopipam</title>
          <description>Active treatment&#xD;
Ecopipam: 50 or 100 mg tablets given once per day for eight weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was an open label study with no placebo control</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Richard Chipkin</name_or_title>
      <organization>Psyadon Pharmaceuticals</organization>
      <phone>3019192020</phone>
      <email>rchipkin@psyadonrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

